



# Rivfloza in Saudi Arabia

*The SFDA named-patient coordination pathway — indicative 2026*

RARE DISEASE · PRIMARY HYPEROXALURIA TYPE 1

## The clinical situation

Rivfloza (nedosiran) is a subcutaneous GalNAc-conjugated siRNA targeting hepatic lactate dehydrogenase (LDHA) mRNA, FDA-approved to lower urinary oxalate in patients aged 9 years and older with primary hyperoxaluria type 1 (PH1) with relatively preserved kidney function (eGFR greater than or equal to 30 mL/min/1.73m<sup>2</sup>). Manufactured by Novo Nordisk (via Dicerna acquisition). Administration is a once-monthly weight-based subcutaneous injection. Pre-treatment workup covers PH1 genetic confirmation, urine oxalate quantitation, and eGFR per FDA labelling.

## The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your nephrologist or metabolic-genetics physician documents PH1 diagnosis, AGXT genotype, eGFR, and Rivfloza rationale.
- 2 Baseline workup.** Urine oxalate quantitation, eGFR, imaging for nephrocalcinosis, hydration plan per FDA labelling.
- 3 SFDA named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, weight-based monthly dosing plan, and chain-of-custody commitment.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with cold-chain 2–8°C shipment.
- 5 Arrival & first dose.** Dispensing pharmacy releases the pre-filled syringe; subcutaneous administration arranged with the treating physician.

## Indicative economics

**Reference US cash-pay range:** USD 490,000–530,000 per year of Rivfloza (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

## Indicative first-dose timing

**7–14 days** from a complete SFDA application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody from Novo Nordisk authorised distribution.

**Documentation.** Physician kit tailored to SFDA review, with PH1 genetic confirmation and eGFR eligibility annex. **Logistics.** Cold-chain 2–8°C internationally tracked shipment with temperature excursion log. **Concierge case lead.** Named point of contact for family and physician through monthly refills. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Rivfloza × Saudi Arabia first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/rivfloza-saudi-arabia.html](https://reservemed.com/access-guides/rivfloza-saudi-arabia.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team